Sanaz Yahyanejad1, Stefan J van Hoof1, Jan Theys1, Lydie M O Barbeau1, Patrick V Granton2, Kim Paesmans1, Frank Verhaegen1, Marc Vooijs3. 1. Department of Radiotherapy (MAASTRO)/GROW - School for Developmental Biology & Oncology, Maastricht University, The Netherlands. 2. Department of Oncology, London Health Sciences Center, Canada. 3. Department of Radiotherapy (MAASTRO)/GROW - School for Developmental Biology & Oncology, Maastricht University, The Netherlands. Electronic address: marc.vooijs@maastrichtuniversity.nl.
Abstract
BACKGROUND AND PURPOSE: Glioblastoma multiforme is the most common malignant brain tumor. Standard treatment including surgery, radiotherapy and chemotherapy with temozolomide is not curative. There is a great need for in vitro and in vivo models closely mimicking clinical practice to ensure better translation of novel preclinical findings. METHODS AND MATERIALS: A 3D spheroid model was established using the U87MG cell line. The efficacy of temozolomide, RT and combinations was assessed using growth delay assays. Orthotopic glioblastoma tumors were established, different radiation doses delivered based on micro-CT based treatment planning (SmART-plan) and dose volume histograms (DVH) were determined. Tumor growth was monitored using bioluminescent imaging. RESULTS: 3D spheroid cultures showed a dose-dependent growth delay upon single and combination treatments. Precise uniform radiation was achieved in all in vivo treatment groups at all doses tested, and DVHs showed accurate dose coverage in the planning target volume which resulted in tumor growth delay. CONCLUSION: We demonstrate that 3D spheroid technology can be reliably used for treatment efficacy evaluation and that mimicking a clinical setting is also possible in small animals. Both these in vitro and in vivo techniques can be combined for clinically relevant testing of novel drugs combined with radiation.
BACKGROUND AND PURPOSE:Glioblastoma multiforme is the most common malignant brain tumor. Standard treatment including surgery, radiotherapy and chemotherapy with temozolomide is not curative. There is a great need for in vitro and in vivo models closely mimicking clinical practice to ensure better translation of novel preclinical findings. METHODS AND MATERIALS: A 3D spheroid model was established using the U87MG cell line. The efficacy of temozolomide, RT and combinations was assessed using growth delay assays. Orthotopic glioblastoma tumors were established, different radiation doses delivered based on micro-CT based treatment planning (SmART-plan) and dose volume histograms (DVH) were determined. Tumor growth was monitored using bioluminescent imaging. RESULTS: 3D spheroid cultures showed a dose-dependent growth delay upon single and combination treatments. Precise uniform radiation was achieved in all in vivo treatment groups at all doses tested, and DVHs showed accurate dose coverage in the planning target volume which resulted in tumor growth delay. CONCLUSION: We demonstrate that 3D spheroid technology can be reliably used for treatment efficacy evaluation and that mimicking a clinical setting is also possible in small animals. Both these in vitro and in vivo techniques can be combined for clinically relevant testing of novel drugs combined with radiation.
Authors: Venus Sosa Iglesias; Stefan J van Hoof; Ana Vaniqui; Lotte Ejr Schyns; Natasja Lieuwes; Ala Yaromina; Linda Spiegelberg; Arjan J Groot; Frank Verhaegen; Jan Theys; Ludwig Dubois; Marc Vooijs Journal: Br J Radiol Date: 2018-11-30 Impact factor: 3.039
Authors: Henry Ruiz-Garcia; Keila Alvarado-Estrada; Paula Schiapparelli; Alfredo Quinones-Hinojosa; Daniel M Trifiletti Journal: Front Cell Neurosci Date: 2020-10-16 Impact factor: 5.505
Authors: Sanaz Yahyanejad; Henry King; Venus Sosa Iglesias; Patrick V Granton; Lydie M O Barbeau; Stefan J van Hoof; Arjan J Groot; Roger Habets; Jos Prickaerts; Anthony J Chalmers; Daniëlle B P Eekers; Jan Theys; Susan C Short; Frank Verhaegen; Marc Vooijs Journal: Oncotarget Date: 2016-07-05
Authors: Alexandra M Mowday; Natasja G Lieuwes; Rianne Biemans; Damiënne Marcus; Behzad Rezaeifar; Brigitte Reniers; Frank Verhaegen; Jan Theys; Ludwig J Dubois Journal: Cancers (Basel) Date: 2020-06-15 Impact factor: 6.639